Rucci Carolyn M. 4

What Happened

• Carolyn M. Rucci, Senior Vice President and Chief Legal Officer of Akebia Therapeutics (AKBA), received two equity awards on January 30, 2026: 190,000 restricted stock units (RSUs) and 270,000 stock options. Both awards were granted at no cash cost to the reporting person (reported acquisition price $0.00), reflecting standard equity compensation rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-30; Form 4 filed: 2026-02-03 (filed within the two-business-day SEC deadline).
• RSUs: 190,000 shares granted under the Issuer’s 2023 Stock Incentive Plan (footnote F1). Vesting: one‑third on each of the first, second and third anniversaries of the grant date, subject to continued service.
• Options (derivative): 270,000 options granted under the 2023 Stock Incentive Plan (footnote F2). Vesting: 25% on the first anniversary, remainder vesting in equal quarterly installments over the following three years, subject to continued service.
• Reported acquisition price for both awards: $0.00 (typical for grants). The filing does not disclose the number of shares owned by Ms. Rucci after these grants in the information provided here.
• Transaction code: A = Award/Grant; derivative indicates stock options. No 10b5-1 plan, tax withholding, or late filing noted in the filing excerpt provided.

Context

• These are compensatory grants, not purchases or sales; they are intended as employee compensation and vest over time, so they do not represent immediate realizable cash value unless/ until vested and exercised/sold.
• For options, vesting and any exercise price (if applicable) determine future value and timing; the filing shows these as option grants (derivative awards) but does not show an exercise price or intrinsic value in this summary.